Intake of Omega 3 in Morbidly Obese Patients

Pontificia Universidade Católica do Rio Grande do Sul

Status

Completed

Conditions

Morbid Obesity

Treatments

Dietary Supplement: Omega 3 intake, morbid obesity

Dietary Supplement: Placebo Capsules

Study type

Interventional

Funder types

Other

Identifiers

NCT02113696

primary

Details and patient eligibility

About

Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?

Full description

Intake of EPA and DHA for the management of morbid obesity in capsules

Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.

Enrollment

46 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women aged between 18-65 years,
BMI > 40 kg/m2 (or > 35 kg/m2 with comorbidities),
ambulatory, receiving an oral diet,
with a diagnosis of metabolic syndrome,
and who signed a Term of Free and Informed Consent.

Exclusion criteria

Systemic inflammatory response syndrome,
coma or compromised organ,
fever or infection foci,
cancer with or without chemotherapy and radiotherapy,
radiotherapy, inflammatory diseases of the gastrointestinal tract,
transplant, trauma, surgery or hospital stay in the past 30 days
use of steroids or non-steroid anti-inflammatory or immunomodulators agents or antibiotics,
or those refusing to take part in the study.